Full Text View
Tabular View
No Study Results Posted
Related Studies
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
This study has been completed.
First Received: November 27, 2006   Last Updated: October 9, 2008   History of Changes
Sponsored by: GlaxoSmithKline
Information provided by: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00404378
  Purpose

This is a two period study of healthy adult subjects to characterize the effect of the dosing of ketoconazole on the the way the body reacts to a dose of GW679769, and to assess the safety profile of oral casopitant with and without ketoconazole. This study will consist of a screening period, two treatment periods and a post-treatment follow-up visit.


Condition Intervention Phase
Healthy Subjects
Drug: ketoconazole
Drug: casopitant
Phase I

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Pharmacokinetics Study
Official Title: An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of [GW679769]

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Plasma levels will be measured for casopitant at Period 1: Day 1, 2 & 3. [ Time Frame: Period 1: Day 1, 2 & 3 ]
  • Plasma levels will be measured for casopitant and ketoconazole at Period 2: Day 4, 5, 6, 7, & 8. [ Time Frame: Period 2: Day 4, 5, 6, 7, & 8. ]

Secondary Outcome Measures:
  • clinical lab tests monitoring of International Normalized Ratio (INR) adverse events vital signs 12 lead ECGs liver function tests [ Time Frame: throughout the study ]

Enrollment: 15
Study Start Date: October 2006
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male or females
  • Females must be of non-childbearing potential
  • Adequate organ functions
  • Able to swallow and retain oral medications
  • Able to understand and comply with study requirements
  • Signed ICF

Exclusion Criteria:

  • Clinically relevant abnormality identified on the screening exam or any other medical condition or circumstance making the subject unsuitable for participation in the study.
  • History of drug or other allergy which contraindicates participation.
  • Known immediate hypersensitivity reaction or idiosyncrasy to GW679769 or ketoconazole or drugs chemically related to the study medications.
  • Use of an investigational drug within 28 days preceding the first dose of GW679769 or ketoconazole or participation in another clinical trial within the past 30 days.
  • Blood donation in excess of 1 pint within 56 days prior to first dose of study medication or intends to donate within 30 days of the post-treatment follow-up visit.
  • History of or suspected iron deficiency.
  • Positive stool for occult blood.
  • Pepsinogen level below the lower limit of laboratory reference range (LLRR).
  • Troponin level above 10% of the coefficient of variation of the assay as determined by the laboratory performing the test.
  • For male subjects, any history of hypogonadism and treatments associated with hypogonadism including radiation therapy to the testicles.
  • For female subjects, a positive serum ß-hCG (beta-human chorionic gonadotropin) pregnancy test.
  • Female subject who is lactating.
  • Positive urine drug screen (UDS) including alcohol.
  • Positive for HIV antibody, hepatitis C antibody or hepatitis B surface antigen
  • Positive urinary cotinine. Subjects must not have used any nicotine-containing products, including nicotine patches or gum, within the past 6 months.
  • Smoking history = 4 packs per day/year or smoked within the past 12 months.
  • History of drug abuse or dependence within the past 6 months.
  • History of alcohol abuse within the past 6 months or alcohol consumption in the past 6 months exceeding study requirements
  • Presence of uncontrolled nausea & vomiting.
  • Presence of an active infection.
  • Any degree of heart failure as defined by the New York Heart Association functional classification system.
  • Active peptic ulcer disease (PUD) or a history of PUD of unknown etiology.
  • Use of any prescription or non-prescription drug(s), herbal or dietary supplements or vitamins within 14 days prior to the first dose of study medication.
  • Consumption of any food or drink containing grapefruit or grapefruit juice, apple juice, Seville oranges, kumquats, pomelos or vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi and brussels sprouts, mustard) within 14 days prior to the first dose of study medication.
  • History of cholecystectomy or biliary tract disease.
  • Any serious or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00404378

Locations
United States, Kansas
GSK Investigational Site
Lenexa, Kansas, United States, 66219
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GSK ( Study Director )
Study ID Numbers: NKV105093
Study First Received: November 27, 2006
Last Updated: October 9, 2008
ClinicalTrials.gov Identifier: NCT00404378     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Casopitant
Pharmacokinetics
Ketoconazole
Healthy subjects
Drug interaction

Study placed in the following topic categories:
Anti-Infective Agents
Antifungal Agents
Healthy
Ketoconazole

Additional relevant MeSH terms:
Anti-Infective Agents
Therapeutic Uses
Antifungal Agents
Ketoconazole
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 03, 2009